TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31033610

Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: ESWT plus eccentric training
Number of subjects: 138

Group type: COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Topical glyceryl trinitrate patch plus eccentric training
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 138
Study: 29060739

Group type: EXPERIMENTAL
Intervention: Game-assisted therapy and conventional therapy
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 13
Study: 27405749

Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (posttetanic count of 1 or 2)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four count of 1 or 2)
Number of subjects: 64
Study: 23271794

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg BID
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg BID
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Concomitant use of a single antiplatelet
Number of subjects: 18113

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet
Number of subjects: 18113
Study: 20705951

Group type: EXPERIMENTAL
Intervention: LPV/r (400mg/100mg) + BILR 355 (150 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: BILR 355/r (150 mg/100mg)
Number of subjects: 34
Study: 19164988

Group type: EXPERIMENTAL
Intervention: Serial nasal bone reduction
Number of subjects: 330

Group type: COMPARATOR
Intervention: Classic nasal bone reduction
Number of subjects: 330
Study: 17958625

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin (50 mg/kg per day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Oral erythromycin
Number of subjects: 132
Study: 15636137

Group type: EXPERIMENTAL
Intervention: Bacterial polycomponent vaccine (VP‐4)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 30
Study: 11452163

Group type: EXPERIMENTAL
Intervention: Previously frozen RBCs stored at 4 degrees C in AS‐3 for 15 days after deglycerolization
Number of subjects: 36

Group type: COMPARATOR
Intervention: Liquid-preserved RBCs stored at 4 degrees C in AS‐1 for 42 days
Number of subjects: 36
Study: 9479761

Group type: EXPERIMENTAL
Intervention: Synchronous condition (tone and noise gated on and off simultaneously)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Asynchronous condition (tone gated on before noise)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Asynchronous condition (noise gated on before tone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Sequential condition (tone offset coinciding with noise onset)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Noise-leading condition
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tone-leading condition
Number of subjects: 6
Study: 8163832

Group type: EXPERIMENTAL
Intervention: Unpassaged influenza B virus isolate [virus U]
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Passaged influenza B virus [virus P]
Number of subjects: 62

Group type: COMPARATOR
Intervention: Uninoculated cell culture medium
Number of subjects: 62
Study: 2778609

Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional toothbrushing, dental floss, and toothpicks
Number of subjects: 40
Study: 4921221

Group type: EXPERIMENTAL
Intervention: Prednisone therapy in Stage I sarcoidosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorambucil or methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31951780

Group type: EXPERIMENTAL
Intervention: Booster dose of polygeline-free inactivated TBE vaccine (Encepur Adults, GSK) administered approximately 3 years post-primary vaccination.
Number of subjects: 0
Study: 30940432

Group type: EXPERIMENTAL
Intervention: Photographic atlas
Number of subjects: 32
Study: 26049975

Group type: EXPERIMENTAL
Intervention: BPS/IC group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 24332196

Group type: EXPERIMENTAL
Intervention: 5 mg ivabradine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 10 mg ivabradine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 20 mg ivabradine
Number of subjects: 36
Study: 21710403

Group type: EXPERIMENTAL
Intervention: No-dose-reduction group (initial optimal therapeutic doses continued throughout the study)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: 4-week group (initial optimal therapeutic doses continued for 4 weeks followed by a half dose reduction)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: 26-week group (initial optimal therapeutic doses continued for 26 weeks followed by a half dose reduction)
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Underweight at study entry
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Normal weight at study entry
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Overweight at study entry
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 374
Study: 19112032

Group type: EXPERIMENTAL
Intervention: Cilostazol 100mg twice a day
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 16228997

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 15178177

Group type: EXPERIMENTAL
Intervention: Dual-task condition (considering both tasks equally important)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Dual-task condition (focusing preferentially on one task)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subjective mental effort rating
Number of subjects: 43

Group type: COMPARATOR
Intervention: Subjective mental effort variation according to task condition
Number of subjects: 43
Study: 11280845

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen A
Number of subjects: 2

Group type: COMPARATOR
Intervention: Chemotherapy regimen B
Number of subjects: 2
Study: 9263085

Group type: EXPERIMENTAL
Intervention: Eltanolone (0.41 +/- 0.1 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Thiopental (2.88 +/- 0.62 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Etomidate (0.26 +/- 0.06 mg/kg)
Number of subjects: 75
Study: 8001359

Group type: EXPERIMENTAL
Intervention: Echocardiography readings by cardiologists
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Echocardiography readings by sonographers
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Echocardiography readings by different sonographers
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Interreader variability assessment
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Intraclass correlation for LVM across visits
Number of subjects: 902
Study: 2963759

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate plus oral placebo (group A, n = 7)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Leuprolide acetate plus oral medroxyprogesterone acetate (group B, n = 9)
Number of subjects: 16
Study: 30457974

Group type: EXPERIMENTAL
Intervention: Open-book online formative assessment covering the topic of the practical course
Number of subjects: 232

Group type: COMPARATOR
Intervention: Formative assessment that did not cover the topic of the practical course
Number of subjects: 232
Study: 29045304

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 35

Group type: COMPARATOR
Intervention: SGA (other than clozapine)
Number of subjects: 35
Study: 26268804

Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA) with dihydroartemisinin plus piperaquine (DHAp)
Number of subjects: 5640

Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration (fMDA) with dihydroartemisinin plus piperaquine (DHAp)
Number of subjects: 5640

Group type: COMPARATOR
Intervention: No mass treatment (standard of care)
Number of subjects: 5640
Study: 23448596

Group type: EXPERIMENTAL
Intervention: Failure-related priming
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Success-related priming
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study: 20890933

Group type: EXPERIMENTAL
Intervention: 220 ng of 2MD
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 440 ng of 2MD
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 18646709

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 2 microg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 microg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (C0 group)
Number of subjects: 60
Study: 16787512

Group type: EXPERIMENTAL
Intervention: Timcodar dimesylate 12.5 mg/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Timcodar dimesylate 50 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 14504873

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg 1 h before operation (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg 1 h before surgery (group N)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Rofecoxib and Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Naproxen sodium and Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rofecoxib and Naproxen sodium
Number of subjects: 60
Study: 10865480

Group type: EXPERIMENTAL
Intervention: Otosporin ear drops
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Otomize ear spray
Number of subjects: 60
Study: 9108642

Group type: EXPERIMENTAL
Intervention: 500 mg b.i.d. sodium valproate (VPA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1,000 mg b.i.d. sodium valproate (VPA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both doses of sodium valproate (VPA)
Number of subjects: 16
Study: 8474201

Group type: EXPERIMENTAL
Intervention: HA-1A (10 mg.kg-1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (human IgM antibody 10 mg.kg-1 and human serum albumin)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HA-1A and combined-controls
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control human IgM antibody
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HA-1A
Number of subjects: 27
Study: 3518984

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg twice daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29623512

Group type: EXPERIMENTAL
Intervention: Feedback group (clinician received a visual display of symptom scores)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (scores were not provided to clinicians)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 27381589

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 750

Group type: COMPARATOR
Intervention: RFC ablation
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 750
Study: 24588407

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy adapted for health care settings (MST‐HC)
Number of subjects: 170

Group type: COMPARATOR
Intervention: In-home family support (control)
Number of subjects: 170
Study: 23350899

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 53
Study: 21813900

Group type: EXPERIMENTAL
Intervention: Short-acting beta agonists
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Long-acting bronchodilators
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease education
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Stage of chronic obstructive pulmonary disease
Number of subjects: 120
Study: 18176319

Group type: EXPERIMENTAL
Intervention: HIV and trauma coping intervention
Number of subjects: 247

Group type: COMPARATOR
Intervention: Therapeutic support group intervention
Number of subjects: 247
Study: 16964692

Group type: EXPERIMENTAL
Intervention: Midwife-assisted smoking cessation intervention (four midwife visits during pregnancy and one after delivery)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Midwife-assisted smoking cessation intervention
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard written information about health risks from maternal smoking to the fetus (control group)
Number of subjects: 205
Study: 14564337

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch (15 mg/24 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11109297

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent (premenstrual only) treatment with SSRIs
Number of subjects: 0
Study: 8866346

Group type: EXPERIMENTAL
Intervention: Tagetes patula preparations plus protective pad
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1471435

Group type: EXPERIMENTAL
Intervention: Comprehensive team care (CC)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Traditional care (TC)
Number of subjects: 262
Study: 6318224

Group type: EXPERIMENTAL
Intervention: Enalapril (5, 10 and 20 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propranolol (40, 80 and 120 mg twice daily)
Number of subjects: 22
Study: 30420001

Group type: EXPERIMENTAL
Intervention: In-treatment expectancy during antidepressant treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gap between expected treatment outcomes and actual depressive severity
Number of subjects: 0
Study: 29853235

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 32
Study: 26813890

Group type: EXPERIMENTAL
Intervention: Dietary α-Linolenic Acid (ALA) intake meeting the recommendation (0.7% of total energy)
Number of subjects: 7202

Group type: EXPERIMENTAL
Intervention: Long-chain n-3 polyunsaturated fatty acids intake meeting the recommendation (≥500 mg/day)
Number of subjects: 7202

Group type: EXPERIMENTAL
Intervention: Both ALA and long-chain n-3 polyunsaturated fatty acids recommendations met
Number of subjects: 7202
Study: 25388488

Group type: EXPERIMENTAL
Intervention: Child feeding training program for primary care health professionals
Number of subjects: 619
Study: 22891212

Group type: EXPERIMENTAL
Intervention: Intravenous administration of triglycerides plus heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of glycerol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 0
Study: 20587704

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 17000647

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous oral progestin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study: 16277782

Group type: EXPERIMENTAL
Intervention: GOS/FOS formula (6 g/l)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bb-12 formula (6.0x10(10) viable cells/litre)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard formula (non-supplemented)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Breast-fed infants (reference group)
Number of subjects: 57
Study: 11997534

Group type: EXPERIMENTAL
Intervention: Radio-frequency (RF) ablation
Number of subjects: 72

Group type: COMPARATOR
Intervention: Percutaneous microwave coagulation (PMC)
Number of subjects: 72
Study: 10542352

Group type: EXPERIMENTAL
Intervention: Texture analysis applied to MR images of the spinal cord in MS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Texture analysis applied to MR images of the spinal cord in relapsing-remitting MS patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Texture analysis technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Segmentation and texture analysis technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Texture analysis
Number of subjects: 0
Study: 7782965

Group type: EXPERIMENTAL
Intervention: Primary-surgical regimen (Group A): total pharyngo‐laryngo‐esophagectomy after 20 Gy irradiation therapy. Chemotherapy was combined in some patients.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Primary-radiotherapeutic regimen (Group B): radiation therapy (60 Gy) with chemotherapy (UFT 300 to 600 mg/day; some patients received 1-2 courses of intravenous cisplatinum).
Number of subjects: 60
Study: 2109951

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (10 micrograms/kg BW/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (10 micrograms/kg BW/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Urapidil (bolus injections of 25, 25 and 50 mg, followed by an infusion of 180 ml/h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (0.35 micrograms/kg BW/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6106469

Group type: EXPERIMENTAL
Intervention: Pindolol (beta-blocking drug)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31220121

Group type: EXPERIMENTAL
Intervention: Cognitive dual task gait training (CDTT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Motor dual task gait training (MDTT)
Number of subjects: 18
Study: 28822566

Group type: EXPERIMENTAL
Intervention: TheraCal
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 27
Study: 25421272

Group type: EXPERIMENTAL
Intervention: Structured allergy intervention (structured allergy history and skin prick testing with tailored advice on allergy avoidance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 24078046

Group type: EXPERIMENTAL
Intervention: Terutroban
Number of subjects: 748

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 748
Study: 21854588

Group type: EXPERIMENTAL
Intervention: Minimally invasive computer-navigated 'femur first' THA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional minimally invasive THA procedure
Number of subjects: 0
Study: 19936457

Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 100 x 10^6 mononuclear cells (Arterial Group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous injection of 100 x 10^6 mononuclear cells (Venous Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 18607802

Group type: EXPERIMENTAL
Intervention: Generalized linear mixed models applied to longitudinal data sequences from clinical studies.
Number of subjects: 0
Study: 16253719

Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa treatment group (n=78), median final dose 2,000 IU/wk
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control/delayed treatment group (n=94), median final dose 3,000 IU/wk
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa treatment group
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control/delayed treatment group
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Patients with stable Hgb levels
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Patients with decreasing Hgb levels
Number of subjects: 172
Study: 11874008

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90

Group type: COMPARATOR
Intervention: Triclofos
Number of subjects: 90

Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 90
Study: 10440619

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 7821104

Group type: COMPARATOR
Intervention: Omeprazole (20 mg/day) alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day) plus plaunotol (240 mg/day)
Number of subjects: 22
Study: 2403470

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Atenolol and Phenelzine (both)
Number of subjects: 4
Study: 331994

Group type: EXPERIMENTAL
Intervention: Guanethidine 3% - adrenaline 0.5% (G-A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30530058

Group type: EXPERIMENTAL
Intervention: Clinical changes in patient symptoms and quality of life
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Small clinical changes in chronically ill adults
Number of subjects: 446
Study: 29354909

Group type: EXPERIMENTAL
Intervention: Acupuncture for 'regaining consciousness, benefiting marrow and opening orifices' and rehabilitation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture along the affected meridians and rehabilitation (Control group)
Number of subjects: 40
Study: 26148681

Group type: EXPERIMENTAL
Intervention: One coaching session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four coaching sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-evaluated communication competence by physicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of consultations by physicians and patients
Number of subjects: 0
Study: 23271305

Group type: EXPERIMENTAL
Intervention: rs2516838 genotype
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: rs2516839 genotype
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: rs2516838 and rs2516839 polymorphisms
Number of subjects: 668
Study: 21645007

Group type: EXPERIMENTAL
Intervention: Plasma transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WBC-containing RBC transfusions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLT transfusions
Number of subjects: 0
Study: 18056855

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 168